The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 31, 2016

Filed:

May. 09, 2014
Applicants:

Southern Research Institute, Birmingham, AL (US);

The Uab Research Foundation, Birmingham, AL (US);

Inventors:

Mark J. Suto, Birmingham, AL (US);

Joanne E. Murphy-Ullrich, Birmingham, AL (US);

Assignee:

Southern Research Institute, Birmingham, AL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 5/08 (2006.01); C07K 5/083 (2006.01); C07K 5/00 (2006.01); A61K 38/04 (2006.01); A61K 38/06 (2006.01); C07K 5/04 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 5/081 (2013.01); A61K 38/04 (2013.01); A61K 38/06 (2013.01); C07K 5/00 (2013.01); C07K 5/04 (2013.01); C07K 5/08 (2013.01); C07K 5/0804 (2013.01); A61K 38/00 (2013.01);
Abstract

The present disclosure relates to compounds, compositions and methods for the treatment of diseases through inhibiting the activity of the transforming growth factor beta (TGF-β). More specifically, the disclosed compounds, compositions and methods are useful in the treatment of certain cancers (e.g. multiple myeloma, hematologic malignancies), diseases associated with excessive TGF-β activity including fibrosis, dermal scarring, immune dysfunction, and bone loss by inhibiting the conversion of latent TGF-β to active TGF-β. A method of preventing the activation of TGF-β in pathology is also provided, comprising administering an amount of the compounds sufficient to inhibit conversion of latent TGF-β to active TGF-β by thrombospondin1 (TSP1), resulting in reduced TGF-β activity and reduced adverse effects such as fibrosis, bone loss, and immune dysfunction.


Find Patent Forward Citations

Loading…